While 2.7 million Canadians suffer from migraine, the condition can be subdivided based on its frequency, said Dr. Esma Dilli, neurologist and clinical assistant professor at the University of British Columbia, during Benefits Canada’s 2019 Vancouver Mental Health Summit on Dec. 12. Episodic migraine is defined by less than 15 headache days a month, whereas […]
Employers should be closely examining the underlying drivers of cost growth in their drug plans, according to a new report by Innovative Medicines Canada. “Typically, [plan sponsors] get their report at the end of the year, they’ll see a cost for their drug plan and they don’t know what’s driving it,” says Joe Farago, the […]
On Dec. 3, the 2019 Face to Face Drug Plan Management Forum featured sessions on rare disease, the pharmaceutical industry’s point of view, legal obligations in drug plan management and a deeper dive into drug programs. Capping coverage for plan members with rare diseases poses an ethical dilemma While high-cost specialty medications represent about 30 […]
While high-cost specialty medications represent about 30 per cent of drug costs, the total budget impact of rare disease drugs is less than two per cent, said Brad McCaw, associate director of market access at Alexion Pharmaceuticals Canada. Within the high-cost specialty market’s top 20 drugs, only one is designated for rare disease, he said […]
Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are getting to the right patients, according to Kathy Sotirakos, senior manager of market access and private insurance at Amgen. Real world evidence will help inform better decision-making from a predictability and outcomes perspective, she said during a panel at […]
As the landscape of Canadian drug plan management continues to evolve, several programs are being implemented by insurers and pharmacy benefits managers to help plan sponsors manage costs. Speaking on a panel at Benefits Canada’s 2019 Face to Face Drug Plan Management Forum on Dec. 3 in Toronto, Ned Pojskic, leader of pharmacy and health provider […]
With Canada’s population ageing and research and development looking to produce medications that are beneficial for this evolving demographic, drugs are becoming more expensive, according to Mitch Frazer, partner and chair of the pensions and employment practice at Torys LLP. In fact, among all the countries in the Organisation for Economic Co-operation and Development, Canada has the third […]
Roughly 3,200 Canadian National Railway Co. workers are on strike with outstanding issues including time-off provisions and lifetime caps on certain benefits. The strike, which began at midnight on Nov. 19, has seen conductors, train personnel and yard workers represented by the Teamsters Canada Rail Conference pushing for further bargaining progress on these issues and others, including safety and fatigue. […]
As the popularity of brand discount cards grows among Canadians, how much are people actually saving? And what’s the cost to insurers? In a study published in the Canadian Medical Association Journal, researchers waded through 2.82 million prescriptions for 89 different medications for which patients used brand discount cards. It found patients saved seven per cent, or $3.49 […]
A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress to vote down the Canada-United States-Mexico trade agreement to prevent extended monopoly rights for pharmaceutical companies in all three countries. The Interfaith Center on Corporate Responsibility, which represents more than 300 religious institutional investors, pension funds, foundations, asset managers […]